Fighting antibiotic resistance-strategies and (pre)clinical developments to find new antibacterials

Antibacterial resistance is one of the greatest threats to human health. The development of new therapeutics against bacterial pathogens has slowed drastically since the approvals of the first antibiotics in the early and mid-20(th) century. Most of the currently investigated drug leads are modifications of approved antibacterials, many of which are derived from natural products. In this review, we highlight the challenges, advancements and current standing of the clinical and preclinical antibacterial research pipeline. Additionally, we present novel strategies for rejuvenating the discovery process and advocate for renewed and enthusiastic investment in the antibacterial discovery pipeline.

Automated summary

Antibacterial resistance is a significant threat to human health, and the development of new therapeutics has slowed down since the first antibiotics were approved in the 20(th) century. Most of the current drug leads are modifications of existing antibacterials, many of which come from natural products. This review highlights the challenges, advancements, and current status of the clinical and preclinical antibacterial research pipeline, and advocates for renewed investment and enthusiasm in the antibacterial discovery process.